Oral & Maxillofacial Surgery, Commanding Officer Military Dental Centre (Gough Lines), Secunderabad, India.
Ann Diagn Pathol. 2019 Jun;40:105-135. doi: 10.1016/j.anndiagpath.2019.04.007. Epub 2019 Apr 24.
Large Unilocular radiolucent lesions of the jaws often present a dilemma to both, the Oral Pathologist and the Maxillofacial surgeon with regards to their accurate diagnosis as well as their most appropriate treatment modality. A precise identification as to whether the lesion is a cyst or a tumor is imperative before any treatment is instituted. Once the correct diagnosis and likely prognosis are established, a management protocol can be planned which will completely eliminate the lesion, while at the same time, ensure least possible morbidity for the patient, such as pathological jaw fractures, persisting neurological deficits, esthetic deformity, functional debility, recurrence/persistence of the lesion, etc. AIM & OBJECTIVES: To establish the value of Immunohistochemistry (IH) as a Diagnostic marker and Prognostic indicator for extensive Unilocular radiolucent lesions of the jaws. To assess its role as an adjunct to Histopathological Examination (HPE) in distinguishing Odontogenic tumours from the cysts, by identifying the former using IH Tumor Markers; and in aiding in selection of the most appropriate and effective treatment option for each of such ambiguous lesions, based on their prognosis as indicated by the expression of lH Cell Proliferation Markers.
Thirty cases of large Unilocular Radiolucent lesions of the jaws (Maxilla/Mandible) were managed over a period of three years. Histopathological examination (HPE) and Immunohistochemical (IH) analysis were carried out of the biopsy specimens in all the cases. Calretinin, an Immunohistochemical Tumor marker, was used to distinguish between Odontogenic cysts and tumours. Ki-67 and Proliferating Cell Nuclear Antigen (PCNA), Immunohistochemical Cell Proliferation markers, provided information on the aggressive potential of the lesions. On the basis of the above information, an appropriate management protocol was established for each of these different lesions. Nerve sparing enucleation and curettage was employed for the established cases of Odontogenic Cysts; Enucleation and curettage, peripheral ostectomy, followed by chemical cauterization was employed for the Unicystic Ameloblastomas and other Odontogenic tumours with a low Ki-67 and PCNA Proliferation Index (PI)/Labelling index (LI ≤ 3); Marginal resection was carried out for the tumours with a higher Labelling Index (LI >3 ≤5), and Segmental resection (including partial/complete Maxillectomy, Hemimandibulectomy with/without disarticulation) for the aggressive pathologies with high Labelling Index (LI > 5).
Of the thirty cases of large Unilocular radiolucent lesions of the Maxilla and Mandible, thirteen were diagnosed as Dentigerous cysts, one as Dentigerous cyst showing Ameloblastomatous transformation; two as Unicystic Ameloblastomas, one as the Mural variant of Unicystic Ameloblastoma; four as Follicular Ameloblastomas, two as Plexiform Ameloblastomas; four as Acanthomatous Ameloblastomas; one as Ameloblastic Fibroma and two as Adenomatoid Odontogenic Tumours. The predictive and prognostic indication of the Immunohistochemical markers correlated well with the post treatment findings.
In cases of extensive Unilocular lesions of the jaws, where ambiguity often exists in both diagnosis and appropriate treatment plan to be employed, Immunohistochemistry can serve as an invaluable tool in establishing the precise diagnosis, guiding the treatment plan, as well as indicating the likely prognosis of these lesions.
颌骨的大而单房透亮病变常给口腔病理学家和颌面外科医生在准确诊断以及选择最合适的治疗方式方面带来困扰。在进行任何治疗之前,必须明确病变是囊肿还是肿瘤。一旦确定了正确的诊断和可能的预后,就可以制定治疗方案,彻底消除病变,同时最大程度地减少患者的发病率,如病理性颌骨骨折、持续存在的神经功能缺损、美容畸形、功能障碍、病变的复发/持续存在等。目的和目标:确定免疫组织化学(IH)作为颌骨大而单房透亮病变的诊断标志物和预后指标的价值。通过使用 IH 肿瘤标志物来识别前者,从而评估其作为组织病理学检查(HPE)的辅助手段,以区分牙源性肿瘤和囊肿;并根据 IH 细胞增殖标志物的表达,为每个具有这种模糊特征的病变选择最合适和最有效的治疗方案,从而辅助选择治疗方案。材料和方法:对 30 例颌骨大而单房透亮病变(上颌骨/下颌骨)进行了为期 3 年的治疗。对所有病例的活检标本进行了组织病理学检查(HPE)和免疫组织化学(IH)分析。钙视网膜蛋白是一种免疫组织化学肿瘤标志物,用于区分牙源性囊肿和肿瘤。Ki-67 和增殖细胞核抗原(PCNA),免疫组织化学细胞增殖标志物,提供了病变侵袭性的信息。根据上述信息,为每个不同的病变制定了适当的治疗方案。对于确定的牙源性囊肿采用神经保留切除术和刮除术;对于单囊型成釉细胞瘤和其他 Ki-67 和 PCNA 增殖指数(PI)/标记指数(LI≤3)较低的牙源性肿瘤,采用切除术和刮除术、外周骨切除术,然后进行化学烧灼;对于 LI 较高(LI>3≤5)的肿瘤,采用边缘切除术,对于 LI>5 的侵袭性病变,采用节段切除术(包括部分/完全上颌骨切除术、带/不带关节分离的下颌骨部分切除术)。结果:在 30 例颌骨大而单房透亮病变中,13 例诊断为含牙囊肿,1 例诊断为含牙囊肿伴牙釉细胞瘤样转化;2 例为单囊型成釉细胞瘤,1 例为单囊型成釉细胞瘤的壁内型;4 例为滤泡型成釉细胞瘤,2 例为丛状型成釉细胞瘤;4 例为棘皮瘤型成釉细胞瘤;1 例为牙源性纤维瘤,2 例为腺牙源性肿瘤。免疫组织化学标志物的预测和预后指示与治疗后的发现密切相关。结论:在颌骨大而单房透亮病变的情况下,在诊断和选择合适的治疗方案方面往往存在不确定性,免疫组织化学可以作为一种非常有价值的工具,用于确定精确的诊断、指导治疗方案,并指示这些病变的可能预后。